Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Oct;58(10):1353-1354.
doi: 10.1007/s40262-019-00815-8.

Authors' Reply to Lechat et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Didier Concordet  1 , Peggy Gandia  1 , Jean-Louis Montastruc  2 , Alain Bousquet-Mélou  1 , Peter Lees  3 , Aude A Ferran  1 , Pierre-Louis Toutain  4   5
Affiliations
Comment

Authors' Reply to Lechat et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Didier Concordet et al. Clin Pharmacokinet. 2019 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, and Pierre-Louis Toutain have no conflicts of interest that are directly relevant to the content of this reply.

Comment on

References

    1. Lechat P, Ropers J, Barré J, Mouly S. Comment on: “Levothyrox® new and old formulations: are they switchable for millions of patients?”. Clin Pharmacokinet. 2019 doi: 10.1007/s40262-019-00814-9. - DOI - PubMed
    1. Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, et al. Authors’ reply to Castello-Bridoux et al.: Comment on: Levothyrox® new and old formulations: are they switchable for millions of patients?”. Clin Pharmacokinet. 2019;58(7):973–975. doi: 10.1007/s40262-019-00786-w. - DOI - PMC - PubMed
    1. Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019;58(7):827–833. doi: 10.1007/s40262-019-00747-3. - DOI - PMC - PubMed
    1. Gottwald-Hostalek U, Uhl W, Wolna P, Kahaly GJ. New levothyroxine formulation meeting 95–105% specification over the whole shelf-life: results from two pharmacokinetic trials. Curr Med Res Opin. 2017;33(2):169–174. doi: 10.1080/03007995.2016.1246434. - DOI - PubMed
    1. Hauck WW, Hyslop T, Chen ML, Patnaik R, Williams RL. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration. Pharm Res. 2000;17(4):375–380. doi: 10.1023/A:1007508516231. - DOI - PubMed

LinkOut - more resources